Press releases

Valby, Denmark, 20 October 2025 – H. Lundbeck A/S (Lundbeck) and Contera Pharma today announced a strategic research collaboration aiming to accelerate the discovery and development of innovative oligonucleotide-based medicines for patients living with serious neurological conditions, where significant unmet medical needs remain. Together, the companies will explore novel RNA-targeting treatment approaches designed to deliver transformative […]

Hørsholm, September 17, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced positive topline results in a Phase 1b pharmacoscintigraphic study evaluating CP-012. CP-012 is an investigational drug designed to address the disabling motor complications of nocturnal immobility and early morning akinesia in Parkinson’s disease. Given the […]

Hørsholm, August 28th, 2025 – Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, today announced that the last patient has been dosed in its Phase 1b pharmacoscintigraphic study of CP-012. CP-012 is a novel delayed-release, dual-pulse levodopa/carbidopa tablet developed to address the debilitating challenges of nocturnal immobility and early morning […]

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the preclinical candidate nomination of CP0014753, a highly potent and selective first-in-class antisense oligonucleotide directed to modulate expression of one of the genes involved in development of Canavan disease. The therapeutic concept behind CP-102 aims to reverse toxic accumulation of […]

[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to announce the appointment of new members to its Board of Directors. These strategic additions reflect Contera Pharma’s commitment to advancing innovative patient-centered therapies. Dr. Mahmoud Mahmoudian, FRS Dr. Mahmoud Mahmoudian brings over 25 […]

Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in a Phase 1b pharmacoscintigraphic study evaluating CP-012. This novel delayed-release, dual-pulse levodopa/carbidopa tablet is designed to address the distinct challenges of nocturnal immobility and early morning akinesia in Parkinson’s disease (PD) patients. These […]